ArticleInternational journal of clinical and experimental pathology2014
Association of nuclear annexin A1 with prognosis of patients with esophageal squamous cell carcinoma.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons.Cells · 2023Review
- TREX1 cytosolic DNA degradation correlates with autoimmune disease and cancer immunity.Clinical and experimental immunology · 2023Article
- Exonucleases: Degrading DNA to Deal with Genome Damage, Cell Death, Inflammation and Cancer.Cells · 2022Review
- Review
- Review
- The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells.Cancers · 2021Article
- Annexin 1-nuclear factor-κB-microRNA-26a regulatory pathway in the metastasis of non-small cell lung cancer.Thoracic cancer · 2019Article
- Advancements of Annexin A1 in inflammation and tumorigenesis.OncoTargets and therapy · 2019Article
- TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133International journal of clinical and experimental pathology · 2019Article
- MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer.Oncology letters · 2018Article
- Annexin A1: Uncovering the Many Talents of an Old Protein.International journal of molecular sciences · 2018Review
- Identification of genes and analysis of prognostic values in nonsmoking females with non-small cell lung carcinoma by bioinformatics analyses.Cancer management and research · 2018Article
- APE1 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis.Oncotarget · 2017Article
- The restorative role of annexin A1 at the blood-brain barrier.Fluids and barriers of the CNS · 2016Review
- Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro.Molecular medicine reports · 2016Article
- Role of intracellular and extracellular annexin A1 in migration and invasion of human pancreatic carcinoma cells.BMC cancer · 2014Article
- Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype.Medical oncology (Northwood, London, England) · 2014Article
- Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer.International journal of clinical and experimental pathology · 2014Article
- The impact of pri-miR-218 rs11134527 on the risk and prognosis of patients with esophageal squamous cell carcinoma.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although recent progress has been made in the diagnosis and treatment of cancer, the prognosis of esophageal squamous cell carcinoma (ESCC) remains poor. The identification of biomarkers for ESCC prognosis is important for treatment decisions. The aim of this study was to evaluate the relationship between the expressions of Annexin A1 (ANXA1), three prime repair exonuclease 1 (TREX1) and apurinic/apyrimidinic endonuclease-1 (APE1) and clinical outcome of patients with ESCC. The expressions of ANXA1, TREX1 and APE1 in 93 pairs of ESCC and paracancerous tissues were tested using immunohistochemistry. ANX1, TREX1 and APE1 were dysregulated in ESCC. Nuclear expressions of ANXA1 and APE1 were significantly associated with pathologic type (P = 0.004 and 0.040, respectively). Patients with low expression of nuclear ANXA1 had a better prognosis than those with high expression of nuclear ANXA1 (HR = 0. 448, 95% CI 0.236-0.849, P = 0.014), especially for those with histologic grade 1 and 2 (HR = 0.303, 95% CI: 0.155-0.593, P < 0.001). In conclusion, nuclear ANXA1 may be potentially used as a prognostic biomarker for ESCC.
Indexed as
Identifiers
24551299PMC3925923W2333066734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.